Han Xiang, You Yunhong, Guo Xiuhui, Ji Youxin, Nie Keke
Department of Oncology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences (Qingdao Central Hospital), Qingdao, 266042, People's Republic of China.
Department of Oncology, Pingdu People's Hospital, Qingdao, 266077, People's Republic of China.
Int J Gen Med. 2024 Nov 25;17:5503-5510. doi: 10.2147/IJGM.S485545. eCollection 2024.
To investigate the efficiency and safety of afatinib in combination with bevacizumab in patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) G719X, S768I, and L861Q mutations.
We retrospective studied treatment naïve patients with local advanced or metastatic non-small cell lung cancer harboring EGFR G719X, S768I, and L861Q mutations from January 2017 to August 2021. EGFR tyrosine kinase inhibitors (TKIs) were the first-line treatment in all patients. The demographic, clinical data and treatment results were collected and analyzed.
A total of 12 Chinese patients were studied. There were seven EGFR G719X mutations, three of the seven patients with single mutation and the others with compound mutations. Four patients had EGFR S768I mutations and one of them with single mutation. Four patients had EGFR L861Q/P mutations and one of them with compound mutations. The overall response rate of the EGFR TKIs treatment was 58.33% (7/12). The median progression-free survival (PFS) was 11.0 months, and median overall survival (OS) was 35.40 months. Two of five (40%) patients had required EGFR T790M mutations after TKIs were resistant. The side effects were mild to moderate hand-foot-syndrome, hypertension, and proteinuria.
Afatinib in combination with bevacizumab are effective and safe in the management of patients with NSCLC harboring EGFR G719X, S768I, L861Q/P single or compound mutations.
探讨阿法替尼联合贝伐单抗治疗表皮生长因子受体（EGFR）G719X、S768I和L861Q突变的非小细胞肺癌（NSCLC）患者的有效性和安全性。
我们回顾性研究了2017年1月至2021年8月间初治的局部晚期或转移性非小细胞肺癌患者，这些患者携带EGFR G719X、S768I和L861Q突变。所有患者均以EGFR酪氨酸激酶抑制剂（TKIs）作为一线治疗。收集并分析患者的人口统计学、临床数据和治疗结果。
共研究了12例中国患者。其中有7例EGFR G719X突变，7例中有3例为单突变，其余为复合突变。4例患者有EGFR S768I突变，其中1例为单突变。4例患者有EGFR L861Q/P突变，其中1例为复合突变。EGFR TKIs治疗的总缓解率为58.33%（7/12）。中位无进展生存期（PFS）为11.0个月，中位总生存期（OS）为35.40个月。5例患者中有2例（40%）在TKIs耐药后出现了EGFR T790M突变。副作用为轻至中度的手足综合征、高血压和蛋白尿。
阿法替尼联合贝伐单抗治疗携带EGFR G719X、S768I、L861Q/P单突变或复合突变的NSCLC患者有效且安全。
